Snapshot from Aug 03, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Cosmos Health share buyback program
Business share repurchase

Cosmos Health share buyback program

Analysis based on 63 articles · First reported Jun 30, 2026 · Last updated Jul 17, 2026

Sentiment
30
Attention
1
Articles
63
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The buyback program signals management's confidence in Cosmos Health's value, potentially supporting the stock price. However, the small market capitalization and low trading volume limit broader market impact.

Pharmaceuticals Healthcare
Event Summary

Cosmos Health Inc. announced a share repurchase program of up to $5 million on June 30, 2026. The company has since repurchased a total of 3,640,000 shares for approximately $700,000, including an additional 220,000 shares at an average price of $0.2229 per share on July 6, 2026. CEO Greg Siokas stated that the buybacks reflect confidence in the company's undervalued shares and commitment to returning capital to shareholders. The program expires on December 31, 2026.

Key Actions
81 Cosmos Health authorized share repurchase
Entities Involved
stock
Cosmos Health
Cosmos Health is executing a $5 million share repurchase program, repurchasing 3.64 million shares for $700,000, signaling management's belief that shares are undervalued.
Importance 100.0 Sentiment 30.0
per
Greg Siokas
CEO Greg Siokas is leading the buyback initiative, expressing confidence in the company's fundamentals and growth prospects.
Importance 50.0 Sentiment 30.0
exch
Nasdaq
Cosmos Health is listed on Nasdaq under ticker COSM; the buyback is a routine corporate action with minimal impact on the exchange.
Importance 10.0 Sentiment 0.0
govactor
United States — United States Securities and Exchange Commission
The SEC regulates the buyback program under Rules 10b5-1 and 10b-18; the company is complying with regulations.
Importance 5.0 Sentiment 0.0
cnt
United States
Cosmos Health is expanding in the US; the buyback is a corporate action with no direct impact on the country.
Importance 5.0 Sentiment 0.0
cnt
United Kingdom
Cosmos Health has operations in the UK; the buyback does not directly affect the country.
Importance 5.0 Sentiment 0.0
stock
Abbott Laboratories
Cana Laboratories is a subsidiary of Cosmos Health; the buyback does not directly affect its operations.
Importance 5.0 Sentiment 0.0
govactor
European Union — European Medicines Agency
The EMA certifies Cana Laboratories; the buyback has no direct impact on this relationship.
Importance 5.0 Sentiment 0.0
priv
ZipDoctor, Inc.
ZipDoctor is a subsidiary of Cosmos Health; the buyback does not directly affect its operations.
Importance 5.0 Sentiment 0.0
cnt
Greece
Cosmos Health has operations in Greece; the buyback does not directly affect the country.
Importance 5.0 Sentiment 0.0
Relationships
Cosmos Health related ↔ Greg Siokas
Cosmos Health related ↔ Abbott Laboratories
Greg Siokas related ↔ Abbott Laboratories
Nasdaq regulated ↔ United States — United States Securities and Exchange Commission Nasdaq operates as a registered national securities exchange under the direct oversight and regulatory authority of the
Nasdaq related ↔ United States
Nasdaq related ↔ United Kingdom
United States — United States Securities and Exchange Commission related ↔ United States
United States — United States Securities and Exchange Commission related ↔ United Kingdom
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
United States related ↔ Abbott Laboratories
United States related ↔ European Union — European Medicines Agency
United States related ↔ Greece
United Kingdom related ↔ European Union — European Medicines Agency
United Kingdom related ↔ Greece
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.